GSK Completes $1.2B Takeover Of US Cancer Drug Biz IDRx
Pharmaceutical giant GSK said Monday that it has completed its acquisition of biopharma company IDRx Inc. in a deal worth up to $1.15 billion in cash to boost its treatment for...To view the full article, register now.
Already a subscriber? Click here to view full article